One Alzheimer’s patient, 12 more months of therapy
NKGen Biotech takes a single-patient look at its natural killer cell therapy to the CTAD conference in Boston. Alzheimer’s trial news usually arrives as averages across dozens or hundreds of people. The poster NKGen Biotech is taking to Boston this month covers exactly one person. The post One Alzhe
<p>NKGen Biotech takes a single-patient look at its natural killer cell therapy to the CTAD conference in Boston. Alzheimer’s trial news usually arrives as averages across dozens or hundreds of people. The poster NKGen Biotech is taking to Boston this month covers exactly one person.
The post One Alzhe</p>